Literature DB >> 15549529

Anticonvulsant drugs in primary headaches prophylaxis.

F Frediani1.   

Abstract

Anticonvulsant drugs have been used in migraine prophylaxis since 1970. In recent years, new antiepileptic medications have given rise to much interest in pain control. Primary headaches prophylaxis is still based on old drugs, and physicians facing these conditions are always prompted to use any new possible choice. Among primary headaches, the most studied drug over last 15 years was divalproex sodium, and many papers showed its efficacy in the treatment of migraine headaches. Valproate is well tolerated and many dosages have been used with success. For the newer drugs, such as gabapentin, lamotrigine or topiramate, evidence is less strong but has been rapidly increasing in the last 5 years. In particular, topiramate has much more evidence of a good efficacy and a safe profile. We review the principal characteristics of their use, according to dosages, lasting of treatments, side effects and significant efficacy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15549529     DOI: 10.1007/s10072-004-0278-4

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  6 in total

Review 1.  Practical considerations for the treatment of elderly patients with migraine.

Authors:  Paola Sarchielli; Maria Luisa Mancini; Paolo Calabresi
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 2.  SARS-CoV-2 Infection, Sex-Related Differences, and a Possible Personalized Treatment Approach with Valproic Acid: A Review.

Authors:  Donatas Stakišaitis; Linas Kapočius; Angelija Valančiūtė; Ingrida Balnytė; Tomas Tamošuitis; Arūnas Vaitkevičius; Kęstutis Sužiedėlis; Daiva Urbonienė; Vacis Tatarūnas; Evelina Kilimaitė; Dovydas Gečys; Vaiva Lesauskaitė
Journal:  Biomedicines       Date:  2022-04-21

3.  Valproic acid increases expression of methylenetetrahydrofolate reductase (MTHFR) and induces lower teratogenicity in MTHFR deficiency.

Authors:  Marc Roy; Daniel Leclerc; Qing Wu; Sapna Gupta; Warren D Kruger; Rima Rozen
Journal:  J Cell Biochem       Date:  2008-10-01       Impact factor: 4.429

4.  Inhibition of the betaine-GABA transporter (mGAT2/BGT-1) modulates spontaneous electrographic bursting in the medial entorhinal cortex (mEC).

Authors:  Misty D Smith; Gerald W Saunders; Rasmus P Clausen; Bente Frølund; Povl Krogsgaard-Larsen; Orla M Larsson; Arne Schousboe; Karen S Wilcox; H Steve White
Journal:  Epilepsy Res       Date:  2008-02-08       Impact factor: 3.045

5.  Analysis of treatment adherence and cost among patients with epilepsy: a four-year retrospective cohort study in Pakistan.

Authors:  Muhammad Arif Asghar; Ahad Abdul Rehman; Muhammad Liaquat Raza; Yousra Shafiq; Muhammad Asif Asghar
Journal:  BMC Health Serv Res       Date:  2021-01-19       Impact factor: 2.655

6.  Antiepileptic drug use, falls, fractures, and BMD in postmenopausal women: findings from the women's health initiative (WHI).

Authors:  Laura D Carbone; Karen C Johnson; John Robbins; Joseph C Larson; J David Curb; Kathleen Watson; Margery Gass; Andrea Z Lacroix
Journal:  J Bone Miner Res       Date:  2010-04       Impact factor: 6.741

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.